Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin, Xiuli Zhang, Heiko Schuster, Étienne Caron, Jeffrey P. Ward, Takuro Noguchi, Yulia Ivanova, Jasreet Hundal, Cora D. Arthur, Willem-Jan Krebber, Gwenn E. Mulder, Mireille Toebes, Matthew D. Vesely, Samuel S.K. Lam, Alan J. Korman, James P. Allison, Gordon J. Freeman, Arlene H. Sharpe, Erika L. Pearce, Ton N. Schumacher, Ruedi Aebersold, Hans-Georg Rammensee, Cornelis J.M. Melief, Elaine R. Mardis, William E. Gillanders, Maxim N. Artyomov, Robert D. Schreiber
Topics & Concepts
ImmunotherapyAntigenBlockadeCancer researchCytotoxic T cellCancer immunotherapyEpitopeImmune checkpointImmunologyBiologyImmunogenicityMonoclonal antibodyImmune systemCancerMedicineAntibodyReceptorIn vitroBiochemistryGeneticsCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy research